健民集团(600976) - 2016 Q1 - 季度财报

Financial Performance - Operating revenue rose by 36.29% to CNY 628,440,869.93 year-on-year[5] - Net profit attributable to shareholders decreased by 9.56% to CNY 23,076,328.02 compared to the same period last year[5] - Basic earnings per share fell by 11.76% to CNY 0.15[5] - Total operating revenue for Q1 2016 was CNY 628,440,869.93, an increase of 36.3% compared to CNY 461,103,761.61 in the same period last year[25] - Net profit for Q1 2016 was CNY 23,092,839.98, a decrease of 13.1% from CNY 26,792,264.99 in Q1 2015[25] - The total comprehensive income attributable to the parent company was CNY 23,076,328.02, compared to CNY 25,515,625.55 in the previous year[26] - The company experienced a decrease in total profit to CNY 16,192,008.03, down from CNY 19,162,689.97 in Q1 2015[28] Cash Flow - Net cash flow from operating activities was negative at CNY -11,359,773.91, a decline of 132.00% year-on-year[5] - The net cash flow from operating activities was negative CNY 11,359,773.91, a significant decline from positive CNY 35,504,053.16 in Q1 2015[31] - Cash inflow from operating activities was CNY 747,500,928.96, compared to CNY 920,561,124.35 in the previous year, indicating a decline of 18.7%[31] - The cash and cash equivalents at the end of the period were $304,082,956.53, compared to $473,465,036.56 in the previous year, indicating a decrease of approximately 35.8%[34] - The total cash increase for the period was $287,384,585.67, down from $361,275,608.05 in the previous year, reflecting a decrease of about 20.4%[34] Assets and Liabilities - Total assets increased by 3.24% to CNY 1,654,001,052.22 compared to the end of the previous year[5] - The company’s total assets increased to ¥1,654,001,052.22, up from ¥1,602,080,122.44 at the beginning of the year[18] - The company’s total liabilities rose to ¥620,755,474.38, compared to ¥592,266,584.58 at the beginning of the year[18] - Total liabilities as of March 31, 2016, were CNY 199,632,370.47, slightly up from CNY 198,826,805.56 at the beginning of the year[23] Shareholder Information - The number of shareholders reached 9,282 at the end of the reporting period[10] - The largest shareholder, Huafang Pharmaceutical Technology Co., Ltd., holds 22.07% of the shares[10] Investment and Expenses - Financial expenses surged by 295.90% to ¥848,931.38, primarily due to a decrease in interest income from the parent company[13] - Investment income from associates rose by 58.50% to ¥5,427,005.75, attributed to the performance growth of Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.[13] - The company reported an investment income of CNY 6,744,009.15, slightly down from CNY 7,693,586.66 in the previous year[25] - The company reported a total of CNY 30,000.00 in government subsidies related to normal business operations[7] - The company reported an increase in sales expenses to CNY 51,565,828.84, up from CNY 36,396,301.58 in the previous year, reflecting a 41.8% rise[27] Future Plans - The company plans to continue expanding its investments in healthcare and pharmaceutical sectors, focusing on strategic partnerships and acquisitions[12]